In September, ONL announced the closing of a $65 million Series D financing round, led by Johnson & Johnson Innovation – JJDC, Inc. The Series D funding supports the advancement of the development of ...

Glaucoma has been called ‘the thief of sight’ because it sneaks up on people. They don’t realize they have it,” said Dr. Anna ...

Patients with osteoporosis who took bisphosphonates, especially risedronate, were at a higher risk of developing acute angle ...

More than 4.2 million Americans live with glaucoma, a leading cause of vision loss in the nation. Although there is no cure for glaucoma, early detection and treatment can stop this condition in its ...

Glaucoma is actually a group of eye diseases that damage the optic nerve in the back of the eye and cause vision loss and ...

Simple reaction time tasks given to patients living with glaucoma had different response times based on whether the task was visual or auditory, according to a new study published in the European ...

Dihydropyridine CCBs may raise the risk of glaucoma, suggests a study published in the Ophthalmology Glaucoma.A study was ...

Sigma-2 receptor modulation using exogenous ligands reduces cellular damage associated with central nervous system degeneration in age-related pathologies such as Alzheimer’s disease, Parkinson’s ...

Some people have labeled glaucoma as the quiet disease, until it steals your vision, and then there are symptoms. In this ...

H-1337 is under clinical development by D. Western Therapeutics Institute and currently in Phase II for Open-Angle Glaucoma.

Some patients with ocular hypertension who develop primary open angle glaucoma experience rapid visual field loss.

Shanghai BDgene Therapeutics is a biotechnology company engaged in research and development of gene therapies for the treatment of genetic diseases. The company is headquartered in Shanghai City, ...